Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α
Cells · 2023
DOI: 10.3390/cells12242791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Sumita Raha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Tay-Sachs Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NCCIH NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Tay-Sachs disease (TSD) is a progressive heritable neurodegenerative disorder characterized by the deficiency of the lysosomal β-hexosaminidase enzyme (Hex−/−) and the storage of GM2 ganglioside, as well as other related glycoconjugates. Along with motor difficulties, TSD patients also manifest a gradual loss of skills and behavioral problems, followed by early death. Unfortunately, there is no cure for TSD; however, research on treatments and therapeutic approaches is ongoing. This study underlines the importance of gemfibrozil (GFB), an FDA-approved lipid-lowering drug, in inhibiting the disease process in a transgenic mouse model of Tay-Sachs. Oral administration of GFB significantly suppressed glial activation and inflammation, while also reducing the accumulation of GM2 gangliosides/glycoconjugates in the motor cortex of Tay-Sachs mice. Furthermore, oral GFB improved behavioral performance and increased the life expectancy of Tay-Sachs mice. While investigating the mechanism, we found that oral administration of GFB increased the level of peroxisome proliferator-activated receptor α (PPARα) in the brain of Tay-Sachs mice, and that GFB remained unable to reduce glycoconjugates and improve behavior and survival in Tay-Sachs mice lacking PPARα. Our results indicate a beneficial function of GFB that employs a PPARα-dependent mechanism to halt the progression of TSD and increase longevity in Tay-Sachs mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.
- Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, 820 South Damen Avenue, Chicago, IL 60612, USA.
ORCID-Profile: Kalipada Pahan
Förderung
- BLRD VA
- NCCIH NIH HHS
- NIA NIH HHS
- NIH HHS
- NIH
- Department of Veterans Affairs
Zitieren
APA
Raha, S., Dutta, D., Paidi, R. K., & Pahan, K. (2023). Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells. https://doi.org/10.3390/cells12242791
Vancouver
Raha S, Dutta D, Paidi RK, Pahan K. Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α. Cells. 2023. doi:10.3390/cells12242791
BibTeX
@article{Raha2023,
author = {Raha, Sumita and Dutta, Debashis and Paidi, Ramesh K and Pahan, Kalipada},
title = {Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor α},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12242791}
}
EUVIMED